
TERUMOBCT



Helping enhance patient care by harnessing the biologic potential of concentrated blood, bone marrow and adipose tissue.

Table of Contents

WHAT ARE AUTOLOGOUS BIOLOGICS?	2
SmartPrep System	
BMAC (Bone Marrow Aspirate Concentrate) System	
Platelet Concentrate System	
AdiPrep Adipose Concentration System	
ABOUT TERUMO BCT	8
KEY FIRSTS: TERUMO BCT	9
CUSTOMER SUPPORT1	0
Clinical support	
Technical support	
REFERENCES 1	2







AUTOLOGOUS BIOLOGICS:

HARNESSING THE POWER OF A PATIENT'S OWN CELLS

WHAT ARE AUTOLOGOUS BIOLOGICS?

Autologous biologic products are created by collecting and concentrating naturally occurring cells from a patient's own body; these products offer physicians alternative options for patients presenting with a wide variety of disorders, injuries and conditions.



During the procedure, cells are drawn from the patient, separated and concentrated using a specialized disposable kit and centrifuge, and then delivered to the application site. Processing can take less than 14 minutes.

Because the biologic is prepared from the patient's own cells, there is a significantly reduced risk of rejection or immune response using autologous biologics as compared to alternative options.^{1,2}



THREE AUTOLOGOUS BIOLOGICS. ONE SYSTEM.

THE ONLY SYSTEM CLEARED TO PROCESS THE THREE MAJOR AUTOLOGOUS BIOLOGICS:

BMA, whole blood and lipoaspirate

The first system to offer One-button processing of bone marrow aspirate, whole blood and lipoaspirate on a single point-of-care platform, the SmartPrep system is designed to deliver a high concentration and optimal composition of autologous regenerative cells.³

The system offers a high level of reproducibility.³ With one-button operation and automated processing that takes 14 minutes or less, the SmartPrep system is simple and easy to use.

The value and flexibility of the SmartPrep system help you limit your capital investment while expanding the options available to your patients.

Clinicians have the freedom to select the autologous biologic they believe will benefit each individual patient most.



BMAC (BONE MARROW ASPIRATE CONCENTRATE) SYSTEM

The BMAC system is used to concentrate bone marrow aspirate (BMA) derived from a patient's own bone marrow.


The concentrated BMA produced using the BMAC system contains a rich mixture of components, including stem cells, progenitor cells, platelets, growth factors, lymphocytes and granulocytes.^{4,5,6}



HIGHER CELL RECOVERY³

THE HIGHER THE CELL RECOVERY, THE MORE CELLS AVAILABLE FOR A SURGEON TO DELIVER TO THE APPLICATION SITE.

BETTER CELL RECOVERY



TNC = Total nucleated cell CFU-F = Colony-forming unit-fibroblast N = 10

TNC P Value: CFU P Value: CD34+ P Value:

 $\begin{array}{ll} \mbox{Biomet-Terumo BCT} = 0.123 & \mbox{Biomet-Terumo BCT} = < 0.001 & \mbox{Biomet-Terumo BCT} = 0.658 \\ \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = < 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbox{Arthrex-Terumo BCT} = 0.001 & \mbox{Arthrex-Terumo BCT} = 0.001 \\ \mbo$



The total nucleated cell (TNC) count found in a BMAC product is typically four times more than that of unconcentrated BMA.⁴

^{*}Based on one study, publication in progress.



PLATELET CONCENTRATE SYSTEM


Platelet-rich plasma (PRP) is plasma that contains a higher concentration of platelets than is typical for whole blood.

While platelet concentration is the primary focus of autologous PRP, preparations also contain growth factors that may help optimize the conditions needed for healing.^{7,8,9}

Other cellular components of PRP include white blood cells and peripheral stem cells. These components all play a biological role in the healing process and are provided at concentrated levels using the platelet concentrate system.



ADIPREP ADIPOSE CONCENTRATION SYSTEM



The AdiPrep system can generate an adipose graft capable of delivering a high concentration of stem cells directly to the application site.¹¹ The chart below shows the concentration of cellular components in a conventional adipose tissue graft.



The AdiPrep system generates a purified, MSC-rich graft in just 4 minutes' processing time.


Cellular Components From the AdiPrep System ¹¹	
Nucleated cells	230,000/mL
Cell viability	78% to 95%

About Terumo BCT



TRUSTED BY CLINICIANS AROUND THE WORLD

Terumo BCT products have been used in more than 4 million cases and counting in hospitals and physicians' offices around the world—including some of the most prestigious and cutting-edge medical centers. Physicians choose Terumo BCT based on the high cell counts in the biologics created, the flexibility of the processing system and the dedicated support that comes with every Terumo BCT product.



A HISTORY OF INNOVATION

A global leader in blood component, therapeutic apheresis and cellular technologies, Terumo BCT entered the cell therapy market more than 40 years ago. Harvest Technologies became our Autologous Biologics business unit in 2015. Its two-decade history in point-of-care autologous biologics^{12,13} was a welcome addition to our cell therapy technologies portfolio.

Terumo BCT provides world-class manufacturing expertise, a well-established global footprint and a strong investment in innovation.





1969 TERU	JFLEX® Blood Bag System, our first blood bag set, is introduced in Japan
	E [®] 2991 Cell Processor begins setting performance standards for numerous processing applications; it is still in use today
devid	E [®] Spectra Apheresis System is the world's first centrifugal separation ce to perform therapeutic plasma exchange with automated fluid nce and anticoagulant management controls
to ha	00, the first process disposable for use with the Harvest SMP-1000 system ave a fixed separation shelf for separating red blood cells from plasma, is red for manufacturing
	Harvest PRP separation system, an automated autologous blood separation em, is cleared
	process disposable designed with floating shelf technology for use with the rtPrep 2 System is cleared for manufacturing
	a Accel® Automated Blood Collection System is the only apheresis em that collects any transfusable component in any combination
2006 BMA	C® (Bone Marrow Aspirate Concentrate) System is cleared
2012 AdiP	rep® Adipose Concentration System is cleared

Customer Support

HERE TO SERVE YOU

As a global leader in cellular technologies and a company with autologous biologics customers in 40 countries, we are proud of our reputation for high-quality products and dedicated customer service. We are committed to actively supporting you with the exceptional service you need to provide quality patient care.



CLINICAL SUPPORT



- Worldwide clinical support to resolve procedural issues
- Available during the busiest clinical hours,
 6 a.m. to 5 p.m. (MT) Monday through Friday,
 excluding U.S. holidays
- In-service and on-site problem-solving available in most regions
- Worldwide device and disposables support
- Technical training classes
- Available during the busiest clinical hours,
 6 a.m. to 5 p.m. (MT) Monday through Friday,
 excluding U.S. holidays
- Field performance support to investigate issues and provide process optimization and system troubleshooting may be available
- Service-level agreements to meet your needs

CUSTOMER SUPPORT

Toll-free (U.S. only): 1.877.842.7837

Direct: 1.303.542.5050

Terumo BCT Autologous Biologics

RISK INFORMATION

These procedures require needle access, possibly resulting in discomfort, tenderness, bruising, swelling, bleeding or pain at the access site, at which there is a small risk of infection. Lightheadedness, fainting, nausea or vomiting may occur.

Before any medical procedure, review prescription and nonprescription medications and any natural or herbal remedies your patient is taking or plans to take.

TO SCHEDULE A MEETING OR TO
LEARN MORE ABOUT TERUMO BCT,
VISIT TERUMOBCT.COM/biologics
OR CALL 1.877.842.7837

TERUMOBCT Autologous Biologics

REFERENCES

¹Safdar A, Shaaban H, Tibayan R, et al. The clinical efficacy of using autologous plateletrich plasma in hip arthroplasty: a retrospective comparative study. J Nat Sci Biol Med. 2015;6(1):49-55.

²Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusionassociated CMV infection after marrow transplant. Blood. 1995;86(9):3598-3603.

³Based on one study, publication in progress, where the BMAC system was compared to Zimmer Biomet BioCUE® Blood and Bone Marrow Aspirate Concentration System and Arthrex Angel® systems.

⁴Hermann PC, Huber SL, Herrier T, et al. Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity. Cell Transplant. 2008;16(10):1059-1069.

^⁵Gianakos A, Sun L, Patel J, Adams D, Liporace F. Clinical application of concentrated bone marrow aspirate in orthopaedics: A systematic review. World J Orthop. 2017;8(6):491.

⁶Hansraj KK. Stem cells in spine surgery. *Surg Technol Int*. 2016;10(29):348-358.

⁷Giusti I, Rughetti A, D'Ascenzo S, et al. Identification of an optimal concentration of platelet gel for promoting angiogenesis in human endothelial cells. Transfusion. 2009;49(4):771-778.

⁸El-Sharkawy H, Kantarci A, Deady J, et al. Platelet-rich plasma: growth factors and pro- and anti-inflammatory properties. J Periodontol. 2007;78(4):661-669.

⁹Fiore S, Serhan C. Lipoxin A4 receptor activation is distinct from that of the formyl peptide receptor in myeloid cells: inhibition of CD11/18 expression by lipoxin A4-lipoxin A4 receptor interaction. Biochemistry. 1995;34(51):16678-16686.


¹⁰Bourin P, Bunnell BA, Casteilla L, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15(6):641-648.

¹¹Internal data. Data on file.

¹²Data Research, Inc. 2015: U.S. market research report for orthopedic cell therapy.

¹³Transparency Market Research. 2016: Platelet-rich plasma market: global industry, size, share, growth, trends and forecast, 2016-2024.





TERUMOBCT As a global leader in blood component, therapeutic apheresis and cellular technologies, we believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. TERUMOBCT.COM

Terumo BCT, Inc. 10811 West Collins

10811 West Collins Ave. Lakewood, Colorado 80215-4440 USA

USA Phone: 1.877.339.4228 Phone: +1.303.231.4357 Fax: +1.303.542.5215

Terumo BCT Europe N.V.

Europe, Middle East and Africa Ikaroslaan 41 1930 Zaventem Belgium Phone: +32.2.715.0590 Fax:+32.2.721.0770

Terumo BCT Asia Pte. Ltd.

89 Science Park Drive #04-25 (Lobby B) The Rutherford Singapore 118261 Phone: +65.6715.3778 Fax: +65.6774.1419

Terumo BCT Latin America S.A.

La Pampa 1517–12th Floor C1428DZE Buenos Aires Argentina Phone: +54.11.5530.5200 Fax: +54.11.5530.5201

Terumo BCT Japan, Inc.

Tokyo Opera City Tower 49F, 3-20-2, Nishi-Shinjuku, Shinjuku-ku, Tokyo 163-1450, Japan Phone: +81.3.6743.7890

Fax: +81.3.6743.9800